Aquestive Therapeutics Inc — Cash Flow (NASDAQ:AQST) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 45.46 M32.98 M9.79 M6.38 M35.76 M 50.45 M Cash from investing activities 517 K913 K2.52 M995 K159 K 492 K Cash from financing activities 28.46 M30.11 M11.56 M3.97 M83.59 M 102.11 M Free cash flow 44.94 M32.07 M7.26 M5.38 M35.6 M 49.96 M

Noticias

Aquestive Therapeutics en la conferencia Oppenheimer: perspectivas estratégicas sobre Anaphylm

Aquestive Therapeutics en Conferencia Oppenheimer: Perspectivas sobre Anaphylm

Aquestive Therapeutics at Oppenheimer Conference: Strategic Insights on Anaphylm

Aquestive nombra al experto en alergias Dr. Greenhawt como director médico

Aquestive nombra al experto en alergias Dr. Greenhawt como director médico

Aquestive appoints allergy expert Dr. Greenhawt as chief medical officer

H.C. Wainwright mantiene calificación de Compra para Aquestive tras respuesta FDA

H.C. Wainwright mantiene calificación de Compra para acciones de Aquestive tras respuesta de la FDA

H.C. Wainwright reiterates Buy rating on Aquestive stock after FDA response

Aquestive Therapeutics, Inc. (AQST) Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film - Slideshow (NASDAQ:AQST) 2026-02-03

Disney, Micron Tech among market cap stock movers on Monday

Aquestive Therapeutics, Inc. (AQST) Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film Transcript